Drug Profile
HIV gp120 vaccine - VaxGen
Alternative Names: AIDSVAX; AIDSVAX B/B'; AIDSVAX B/E; HIV gp120 vaccine - Genentech; HIV gp120 vaccine AIDSVAX - VaxGen; HIV vaccine AIDSVAX - VaxGen; rgp120/HIV-1MNLatest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Genentech; VaxGen
- Developer Centre Hospitalier Universitaire Vaudois; EuroVacc Foundation; Genentech; Global Solutions for Infectious Diseases; International AIDS Vaccine Initiative; MRC/UVRI Uganda Research Unit on AIDS; VaxGen
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for phase-I development in HIV-1-infections(In neonates, Prevention) in Puerto Rico (IM, Injection)
- 28 Aug 2022 No recent reports of development identified for phase-I development in HIV-1-infections(In neonates, Prevention) in USA (IM, Injection)
- 07 Aug 2018 National Institute of Allergy and Infectious Diseases plans a phase I trial for HIV Infections in October 2018 (NCT03618056)